Post-pandemic Era Global Brucellosis Vaccines Market Segment Research Report 2024
Summary
The global economy is expected to expand 5.6% in 2021，global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach global herd immunity. However, the recovery in many countries is being held back by a resurgence of COVID-19 cases and lagging vaccination progress, as well as the withdrawal of policy support in some instances.
The annual U.S. economic growth rate slipped to -3.5% in 2020, but grew at a yearly pace of more than 6% in the previous two quarters of 2021. The economy of continental Europe bounced back in the second quarter after having contracted in both the fourth quarter of 2020 and the first quarter of 2021, as the vaccinations accelerated, and governments eased restrictions. Among major economies, the annualized growth rate was 6.1% in Germany, 3.6% in France, 11.2% in Italy, and 11.7% in Spain. The especially rapid growth in Spain and Italy was attributed to a surge in consumer spending, likely the result of an easing of economic restrictions.
Regional Economic ProspectsGrowth in the East Asia and Pacific is projected to accelerate by 7.7% in 2021, Central Asia is forecast to grow by 3.9% this year, economic activity in the Middle East and North Africa is forecast to advance by 2.4%, South Asia is projected to expand by 6.8%.
The global Brucellosis Vaccines market size was USD XX billion in 2021. It is likely to progress at a CAGR of XX% during the forecast period of 2022-2027, according to MR Accuracy Reports analysis, The segment in Brucellosis Vaccines market is estimated to reach a market value of USD XX billion by 2021 from an initial market value of USD XX billion in 2021. China market value in 2021 is about USD XX billion, and China Brucellosis Vaccines production is XX (K Units). US market value in 2021 is about USD XX billion, and US Brucellosis Vaccines production is XX (K Units). Europe market value in 2021 is about USD XX billion, and Europe Brucellosis Vaccines production is XX (K Units).
Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Brucellosis Vaccines Market by MR Accuracy Reports Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Brucellosis Vaccines Market?
Jinyu
Colorado Serum
Boehringer Ingelheim
Biogenesis-Bago
Vetal Company
CZ Veterinaria
SYVA Laboratorios
Indian Immunologicals
Qilu
Tecnovax
Hester Biosciences
Zoetis
Onderstepoort Biological
Instituto Rosenbusch
Ceva Sante Animale
Calier & Biologicos Laverlam
Biovet
Major Type of Brucellosis Vaccines Covered in MR Accuracy Reports report
S19 Vaccine
RB51 Vaccine Strain
Other
Application Segments Covered in MR Accuracy Reports Market
Cattle
Sheep
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Content
Table of Contents
Global Brucellosis Vaccines Market Segment Research Report 2021
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Brucellosis Vaccines Market by Value
2.2.1 Global Brucellosis Vaccines Revenue by Type
2.2.2 Global Brucellosis Vaccines Market by Value (%)
2.3 Global Brucellosis Vaccines Market by Production
2.3.1 Global Brucellosis Vaccines Production by Type
2.3.2 Global Brucellosis Vaccines Market by Production (%)
3. The Major Driver of Brucellosis Vaccines Industry
3.1 Historical & Forecast Global Brucellosis Vaccines Demand
3.2 Largest Application for Brucellosis Vaccines (2017-2027)
3.3 The Major Downstream Company in China Market 2021
4. Global and Regional Brucellosis Vaccines Market
4.1 Regional Market Size in Terms of Production & Demand (2021)
4.2 Regional Market Share in Terms of Revenue (2019-2027)
4.3 Concentration Ratio (CR5& CR10) of Brucellosis Vaccines Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Brucellosis Vaccines Production, Demand (2017-2027)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
6. Europe Brucellosis Vaccines Production, Demand (2017-2027)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
7. China Brucellosis Vaccines Production, Demand (2017-2027)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
8. Japan Brucellosis Vaccines Production, Demand (2017-2027)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
9. India Brucellosis Vaccines Production, Demand (2017-2027)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
10. Korea Brucellosis Vaccines Production, Demand (2017-2027)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
11. Southeast Asia Brucellosis Vaccines Production, Demand (2017-2027)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
12. Global Brucellosis Vaccines Average Price Trend
12.1 Market Price for Each Type of Brucellosis Vaccines in US (2017-2021)
12.2 Market Price for Each Type of Brucellosis Vaccines in Europe (2017-2021)
12.3 Market Price for Each Type of Brucellosis Vaccines in China (2017-2021)
12.4 Market Price for Each Type of Brucellosis Vaccines in Japan (2017-2021)
12.5 Market Price for Each Type of Brucellosis Vaccines in India (2017-2021)
12.6 Market Price for Each Type of Brucellosis Vaccines in Korea (2017-2021)
12.7 Market Price for Each Type of Brucellosis Vaccines in Southeast Asia (2017-2021)
13. Industrial Chain (Impact of COVID-19)
13.1 Brucellosis Vaccines Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Technology Trends of Brucellosis Vaccines
14. Brucellosis Vaccines Competitive Landscape
14.1 Jinyu
14.1.1 Jinyu Company Profiles
14.1.2 Jinyu Product Introduction
14.1.3 Jinyu Brucellosis Vaccines Sales, Revenue (2017-2021)
14.1.4 Strategic initiatives
14.2 Colorado Serum
14.2.1 Colorado Serum Company Profiles
14.2.2 Colorado Serum Product Introduction
14.2.3 Colorado Serum Brucellosis Vaccines Sales, Revenue (2017-2021)
14.2.4 Strategic initiatives
14.3 Boehringer Ingelheim
14.3.1 Boehringer Ingelheim Company Profiles
14.3.2 Boehringer Ingelheim Product Introduction
14.3.3 Boehringer Ingelheim Brucellosis Vaccines Sales, Revenue (2017-2021)
14.3.4 Strategic initiatives
14.4 Biogenesis-Bago
14.4.1 Biogenesis-Bago Company Profiles
14.4.2 Biogenesis-Bago Product Introduction
14.4.3 Biogenesis-Bago Brucellosis Vaccines Sales, Revenue (2017-2021)
14.4.4 Strategic initiatives
14.5 Vetal Company
14.5.1 Vetal Company Company Profiles
14.5.2 Vetal Company Product Introduction
14.5.3 Vetal Company Brucellosis Vaccines Sales, Revenue (2017-2021)
14.5.4 Strategic initiatives
14.6 CZ Veterinaria
14.6.1 CZ Veterinaria Company Profiles
14.6.2 CZ Veterinaria Product Introduction
14.6.3 CZ Veterinaria Brucellosis Vaccines Sales, Revenue (2017-2021)
14.6.4 Strategic initiatives
14.7 SYVA Laboratorios
14.7.1 SYVA Laboratorios Company Profiles
14.7.2 SYVA Laboratorios Product Introduction
14.7.3 SYVA Laboratorios Brucellosis Vaccines Sales, Revenue (2017-2021)
14.7.4 Strategic initiatives
14.8 Indian Immunologicals
14.8.1 Indian Immunologicals Company Profiles
14.8.2 Indian Immunologicals Product Introduction
14.8.3 Indian Immunologicals Brucellosis Vaccines Sales, Revenue (2017-2021)
14.8.4 Strategic initiatives
14.9 Qilu
14.9.1 Qilu Company Profiles
14.9.2 Qilu Product Introduction
14.9.3 Qilu Brucellosis Vaccines Sales, Revenue (2017-2021)
14.9.4 Strategic initiatives
14.10 Tecnovax
14.10.1 Tecnovax Company Profiles
14.10.2 Tecnovax Product Introduction
14.10.3 Tecnovax Brucellosis Vaccines Sales, Revenue (2017-2021)
14.10.4 Strategic initiatives
14.11 Hester Biosciences
14.12 Zoetis
14.13 Onderstepoort Biological
14.14 Instituto Rosenbusch
14.15 Ceva Sante Animale
14.16 Calier & Biologicos Laverlam
14.17 Biovet
15. Conclusion
List of Figure
List of Tables and Figures
Figure 1. Total Demand by Application of Brucellosis Vaccines Industry (Volume)
Figure 2. Brucellosis Vaccines Production & Demand by Regions in 2021
Figure 3. Regional Market Share in Terms of Revenue (2021&2027)
Figure 4. The Top 10 and 5 Players Market Share by Brucellosis Vaccines Revenue in 2021
Figure 5. US Brucellosis Vaccines Production, Demand (2017-2027)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Brucellosis Vaccines Production, Demand (2017-2027)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Brucellosis Vaccines Production, Demand (2017-2027)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Brucellosis Vaccines Production, Demand (2017-2027)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Brucellosis Vaccines Production, Demand (2017-2027)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Brucellosis Vaccines Production, Demand (2017-2027)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Brucellosis Vaccines Production, Demand (2017-2027)
Figure 43. Current and Estimated Production Breakdown by Type (2017-2027)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Brucellosis Vaccines Revenue, by Type (Million USD) (2017-2027)
Table 4. Brucellosis Vaccines Production, by Type (K Unit) (2017-2027)
Table 5. Brucellosis Vaccines Demand (K Unit) by Application (2017-2027)
Table 6. Brucellosis Vaccines Demand (Million USD) by Application (2017-2027)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2021)
Table 9. Regional Market Share in Terms of Revenue (2021&2027)
Table 10. Ranking of Global Top Brucellosis Vaccines Companies by Revenue, Concentration Ratio in 2021
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Brucellosis Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 13. Current and Estimated Production Breakdown by Type (2017-2027)
Table 14. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 15. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Brucellosis Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 19. Current and Estimated Production Breakdown by Type (2017-2027)
Table 20. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 21. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Brucellosis Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Brucellosis Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 30. Current and Estimated Production Breakdown by Type (2017-2027)
Table 31. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 32. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Brucellosis Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 36. Current and Estimated Production Breakdown by Type (2017-2027)
Table 37. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 38. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Brucellosis Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 42. Current and Estimated Production Breakdown by Type (2017-2027)
Table 43. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 44. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Brucellosis Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 48. Table Current and Estimated Demand Breakdown by Type (2017-2027)
Table 49. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Brucellosis Vaccines in US (2017-2021)
Table 53. Market Price (USD/Unit) for Each Type of Brucellosis Vaccines in Europe (2017-2021)
Table 54. Market Price (USD/Unit) for Each Type of Brucellosis Vaccines in China (2017-2021)
Table 55. Market Price (USD/Unit) for Each Type of Brucellosis Vaccines in Japan (2017-2021)
Table 56. Market Price (USD/Unit) for Each Type of Brucellosis Vaccines in India (2017-2021)
Table 57. Market Price (USD/Unit) for Each Type of Brucellosis Vaccines in Korea (2017-2021)
Table 58. Market Price (USD/Unit) for Each Type of Brucellosis Vaccines in Southeast Asia (2017-2021)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Jinyu Profiles
Table 61. Jinyu Brucellosis Vaccines Product Introduction
Table 62. Jinyu Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 63. Jinyu Strategic initiatives
Table 64. Colorado Serum Profiles
Table 65. Colorado Serum Brucellosis Vaccines Product Introduction
Table 66. Colorado Serum Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 67. Colorado Serum Strategic initiatives
Table 68. Boehringer Ingelheim Profiles
Table 69. Boehringer Ingelheim Brucellosis Vaccines Product Introduction
Table 70. Boehringer Ingelheim Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 71. Boehringer Ingelheim Strategic initiatives
Table 72. Biogenesis-Bago Profiles
Table 73. Biogenesis-Bago Brucellosis Vaccines Product Introduction
Table 74. Biogenesis-Bago Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 75. Biogenesis-Bago Strategic initiatives
Table 76. Vetal Company Profiles
Table 77. Vetal Company Brucellosis Vaccines Product Introduction
Table 78. Vetal Company Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 79. Vetal Company Strategic initiatives
Table 80. CZ Veterinaria Profiles
Table 81. CZ Veterinaria Brucellosis Vaccines Product Introduction
Table 82. CZ Veterinaria Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 83. CZ Veterinaria Strategic initiatives
Table 84. SYVA Laboratorios Profiles
Table 85. SYVA Laboratorios Brucellosis Vaccines Product Introduction
Table 86. SYVA Laboratorios Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 87. SYVA Laboratorios Strategic initiatives
Table 88. Indian Immunologicals Profiles
Table 89. Indian Immunologicals Brucellosis Vaccines Product Introduction
Table 90. Indian Immunologicals Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 91. Indian Immunologicals Strategic initiatives
Table 92. Qilu Profiles
Table 93. Qilu Brucellosis Vaccines Product Introduction
Table 94. Qilu Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 95. Qilu Strategic initiatives
Table 97. Tecnovax Profiles
Table 98. Tecnovax Brucellosis Vaccines Product Introduction
Table 99. Tecnovax Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 100. Tecnovax Strategic initiatives
Table 101. Hester Biosciences Profiles
Table 102. Hester Biosciences Brucellosis Vaccines Product Introduction
Table 103. Hester Biosciences Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 104. Hester Biosciences Strategic initiatives
Table 105. Zoetis Profiles
Table 106. Zoetis Brucellosis Vaccines Product Introduction
Table 107. Zoetis Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 108. Zoetis Strategic initiatives
Table 109. Onderstepoort Biological Profiles
Table 110. Onderstepoort Biological Brucellosis Vaccines Product Introduction
Table 111. Onderstepoort Biological Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 112. Onderstepoort Biological Strategic initiatives
Table 113. Instituto Rosenbusch Profiles
Table 114. Instituto Rosenbusch Brucellosis Vaccines Product Introduction
Table 115. Instituto Rosenbusch Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 116. Instituto Rosenbusch Strategic initiatives
Table 117. Ceva Sante Animale Profiles
Table 118. Ceva Sante Animale Brucellosis Vaccines Product Introduction
Table 119. Ceva Sante Animale Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 120. Ceva Sante Animale Strategic initiatives
Table 121. Calier & Biologicos Laverlam Profiles
Table 122. Calier & Biologicos Laverlam Brucellosis Vaccines Product Introduction
Table 123. Calier & Biologicos Laverlam Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 124. Calier & Biologicos Laverlam Strategic initiatives
Table 125. Biovet Profiles
Table 126. Biovet Brucellosis Vaccines Product Introduction
Table 127. Biovet Brucellosis Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices